Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QNWR | ISIN: US8808811074 | Ticker-Symbol: 430
Tradegate
18.09.25 | 10:16
6,400 Euro
+1,59 % +0,100
1-Jahres-Chart
TERNS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TERNS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,3006,45011:07
6,3006,45011:01

Aktuelle News zur TERNS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBarclays initiates Terns Pharmaceuticals stock with Overweight rating1
MiBarclays stuft Terns Pharmaceuticals mit "Overweight" ein und sieht Milliardenpotenzial9
20.08.Terns Pharmaceuticals stock rating reiterated at Mizuho amid oral GLP-1 market shifts6
06.08.Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets20
06.08.Terns Pharmaceuticals, Inc. Loss At -$24.09 Mln In Q24
05.08.Terns Pharmaceuticals GAAP EPS of -$0.26 beats by $0.034
05.08.Terns Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
TERNS PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.08.Terns Pharmaceuticals, Inc. - 8-K, Current Report1
23.06.Terns completes enrollment in Phase 2 obesity drug trial7
23.06.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions204Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment...
► Artikel lesen
17.06.Citizens JMP reiterates Terns Pharmaceuticals stock rating on positive data2
16.06.Terns Pharmaceuticals, Inc. - 8-K, Current Report1
14.05.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-7015
13.05.BMO Capital cuts Terns Pharma stock target to $15, keeps Outperform 16
09.05.Terns Pharmaceuticals GAAP EPS of -$0.262
02.05.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)228FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
21.04.JMP maintains $20 target on Terns stock amid GLP-1RA developments6
15.04.Mizuho maintains Outperform on Terns Pharma, $14 target5
02.04.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)185FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
► Artikel lesen
20.03.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates229Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase...
► Artikel lesen
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1